Floatz logo

Eflornithine

Astrocytoma

Orbus Therapeutics, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Astrocytoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Oliver Jonas
Phase 2BB
Irinotecan
Julie Krystal
Phase 2BB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB

View all 40 →

Same molecule, other indications

Eflornithine is also rated in:

classic familial adenomatous polyposisDormant
BB
Indicative ·
66 / 100
View asset →
precancerous conditionDormant
BB
Indicative ·
64 / 100
View asset →
colon adenomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →